[{"data":1,"prerenderedAt":1020},["ShallowReactive",2],{"page-\u002Fmedvi-reviews":3},{"id":4,"title":5,"body":6,"category":978,"description":979,"extension":980,"meta":981,"navigation":982,"path":983,"publishedAt":984,"review":985,"seo":1014,"sitemap":1015,"stem":1018,"thumbnail":52,"updatedAt":984,"__hash__":1019},"content\u002Fmedvi-reviews.md","Medvi Reviews (2026) — GLP-1 Telehealth, Pricing & Verdict",{"type":7,"value":8,"toc":940},"minimark",[9,29,39,46,53,59,64,158,175,179,182,201,204,208,213,223,227,230,234,244,248,259,265,270,274,280,328,333,362,368,372,387,401,407,426,436,440,445,466,477,481,487,493,499,505,511,515,519,537,541,563,567,570,574,580,674,677,681,684,716,722,726,729,752,759,765,770,774,828,832,844,860,866,870,874,877,881,884,888,891,895,898,902,905,909,912,916,923,927,930,934],[10,11,12,16,17,20,21,24,25,28],"p",{},[13,14,15],"strong",{},"Medvi reviews"," in 2026 usually mean one thing: is ",[13,18,19],{},"MEDVi"," (medvi.org \u002F medvi.io) a safe, fair way to get GLP-1 weight-loss medication without an in-person clinic — or a billing trap wrapped in telehealth marketing? This NexReview guide separates the ",[13,22,23],{},"clinical convenience"," many patients like from the ",[13,26,27],{},"pricing, compounding, and regulatory"," issues you must understand before you pay.",[10,30,31,34,35,38],{},[13,32,33],{},"Important:"," This is not medical advice, not a prescription recommendation, and not a guarantee of weight loss. Semaglutide and tirzepatide can cause serious side effects. Discuss eligibility, contraindications, and monitoring with a licensed clinician. Compounded products are ",[13,36,37],{},"not"," the same as FDA-approved brand drugs, even when ads imply otherwise.",[10,40,41,42,45],{},"Also: ",[13,43,44],{},"MEDVi ≠ MEDvidi."," MEDVi is a GLP-1 weight telehealth brand. MEDvidi is a separate mental-health telehealth company. Mixing their review scores is a common error online.",[10,47,48],{},[49,50],"img",{"alt":51,"src":52},"Medvi Reviews (2026) — GLP-1 Telehealth, Pricing & Verdict — hero","\u002Fimages\u002Fmedvi-reviews.webp",[10,54,55],{},[56,57,58],"em",{},"Telehealth weight-care context — Wikimedia Commons",[60,61,63],"h2",{"id":62},"medvi-reviews-snapshot-2026","Medvi Reviews Snapshot (2026)",[65,66,67,80],"table",{},[68,69,70],"thead",{},[71,72,73,77],"tr",{},[74,75,76],"th",{},"Question",[74,78,79],{},"Short answer",[81,82,83,92,100,108,116,124,136,147],"tbody",{},[71,84,85,89],{},[86,87,88],"td",{},"What is MEDVi?",[86,90,91],{},"US cash-pay telehealth for compounded (and some brand) GLP-1 weight programs",[71,93,94,97],{},[86,95,96],{},"Main meds",[86,98,99],{},"Compounded semaglutide & tirzepatide — injection or daily tablet options commonly marketed",[71,101,102,105],{},[86,103,104],{},"Typical entry prices (verify live)",[86,106,107],{},"Semaglutide often ~$179\u002Fmo entry; tirzepatide often ~$279–$299\u002Fmo range in 2026 coverage",[71,109,110,113],{},[86,111,112],{},"Insurance?",[86,114,115],{},"Generally cash-pay; do not assume coverage",[71,117,118,121],{},[86,119,120],{},"Trustpilot vibe",[86,122,123],{},"Large sample, often ~4.4+ — convenience & results praised",[71,125,126,129],{},[86,127,128],{},"BBB vibe",[86,130,131,132,135],{},"Frequently ",[13,133,134],{},"F",", not accredited — billing\u002Fcancel\u002Frefund clusters",[71,137,138,141],{},[86,139,140],{},"Regulatory flag",[86,142,143,146],{},[13,144,145],{},"FDA warning letter (Feb 2026)"," on misbranding \u002F misleading claims",[71,148,149,152],{},[86,150,151],{},"NexReview score",[86,153,154,157],{},[13,155,156],{},"6.8\u002F10"," — usable access, weak transparency on price & compounding claims",[10,159,160,163,164,166,167,170,171,174],{},[13,161,162],{},"Editorial stance:"," Many ",[13,165,15],{}," are genuinely positive about the ",[56,168,169],{},"service experience",". That does not cancel regulator findings about ",[56,172,173],{},"how the product was marketed",", nor patient complaints about month-two pricing and cancellations.",[60,176,178],{"id":177},"what-is-medvi","What Is MEDVi?",[10,180,181],{},"MEDVi is a US telehealth platform focused on medically supervised weight management using GLP-1 pathway drugs. The typical funnel:",[183,184,185,189,192,195,198],"ol",{},[186,187,188],"li",{},"Online medical intake (history, meds, goals, BMI-related questions)",[186,190,191],{},"Virtual review\u002Fconsult with a US-licensed provider",[186,193,194],{},"If appropriate, a prescription for compounded and\u002For brand GLP-1 options",[186,196,197],{},"Pharmacy fulfillment shipped to your door",[186,199,200],{},"Ongoing messaging \u002F support for dose questions and side effects",[10,202,203],{},"Availability is commonly described as covering most US states (third-party guides often note exclusions such as Mississippi due to telehealth rules — confirm for your ZIP at signup). Lab requirements are not always mandatory up front in marketing copy; some patients still get labs recommended. Always answer intake honestly — GLP-1 drugs are not lifestyle candy.",[60,205,207],{"id":206},"medications-compounded-vs-brand","Medications: Compounded vs Brand",[209,210,212],"h3",{"id":211},"compounded-semaglutide","Compounded semaglutide",[10,214,215,216,218,219,222],{},"Compounded semaglutide is prepared by a compounding pharmacy and is ",[13,217,37],{}," FDA-approved as Wegovy® or Ozempic®. Ads that say “same active ingredient as…” are exactly the kind of framing the FDA has scrutinized industry-wide. Pharmacokinetics, inactive ingredients, quality systems, and labeling can differ. Treat brand trial data as ",[13,220,221],{},"context",", not a copy-paste promise for a compounded vial or tablet.",[209,224,226],{"id":225},"compounded-tirzepatide","Compounded tirzepatide",[10,228,229],{},"Same caution for tirzepatide relative to Mounjaro® \u002F Zepbound®. Dual GIP\u002FGLP-1 biology is why many patients seek this molecule; that still does not make a compounded product FDA-evaluated for safety and effectiveness the way the brand is.",[209,231,233],{"id":232},"oral-tablets-vs-injections","Oral tablets vs injections",[10,235,236,237,240,241,243],{},"MEDVi is frequently cited among telehealth brands offering ",[13,238,239],{},"oral tablet"," formats alongside weekly injectables. Tablets can feel easier if you hate needles — they do ",[13,242,37],{}," erase GI side effects, and a compounded oral product is not identical to FDA-approved oral semaglutide formulations engineered for absorption.",[209,245,247],{"id":246},"brand-name-membership-paths","Brand-name membership paths",[10,249,250,251,254,255,258],{},"Some coverage describes brand GLP-1s under a separate membership (e.g. ~$99\u002Fmo membership ",[13,252,253],{},"plus"," medication cost). If insurance or brand preference matters to you, get the ",[13,256,257],{},"all-in monthly number in writing"," before checkout.",[10,260,261],{},[49,262],{"alt":263,"src":264},"Medvi Reviews (2026) — medications and care path","\u002Fimages\u002Fmedvi-reviews-world.webp",[10,266,267],{},[56,268,269],{},"Medication and monitoring mindset — Wikimedia Commons",[60,271,273],{"id":272},"pricing-the-month-two-problem","Pricing: The Month-Two Problem",[10,275,276,277,279],{},"Independent ",[13,278,15],{}," in 2026 repeatedly describe:",[65,281,282,295],{},[68,283,284],{},[71,285,286,289,292],{},[74,287,288],{},"Plan type (reported)",[74,290,291],{},"Approx. street framing",[74,293,294],{},"Watch-out",[81,296,297,307,317],{},[71,298,299,301,304],{},[86,300,212],{},[86,302,303],{},"From ~$179\u002Fmo at entry",[86,305,306],{},"May rise after intro \u002F dose changes",[71,308,309,311,314],{},[86,310,226],{},[86,312,313],{},"From ~$279–$299\u002Fmo",[86,315,316],{},"Same — ask maintenance price",[71,318,319,322,325],{},[86,320,321],{},"Brand path",[86,323,324],{},"Membership + drug cost",[86,326,327],{},"Can dwarf compounded cash rates",[10,329,330],{},[13,331,332],{},"What to ask before you pay",[334,335,336,350,353,356,359],"ul",{},[186,337,338,339,342,343,346,347],{},"Exact price for ",[13,340,341],{},"month 1",", ",[13,344,345],{},"month 2",", and ",[13,348,349],{},"maintenance dose",[186,351,352],{},"Whether price is flat across all doses (many competitors advertise this; complaints say MEDVi often does not feel flat)",[186,354,355],{},"What “money-back \u002F results guarantee” actually requires (multi-month adherence, fee deductions, narrow qualification)",[186,357,358],{},"Cancel cutoff relative to next shipment\u002Fcharge",[186,360,361],{},"Whether labs, shipping, or supplies ever bill separately",[10,363,364,367],{},[13,365,366],{},"Budget reality:"," GLP-1 therapy is multi-month. If you can only afford the intro price, you are not ready for the program.",[60,369,371],{"id":370},"fda-warning-letter-february-2026","FDA Warning Letter (February 2026)",[10,373,374,375,378,379,382,383,386],{},"On ",[13,376,377],{},"20 February 2026",", FDA CDER issued MEDVi, LLC a ",[13,380,381],{},"warning letter"," (public correspondence around reference ",[13,384,385],{},"721455",") after reviewing website content. Independent summaries of the letter highlight two themes:",[183,388,389,395],{},[186,390,391,394],{},[13,392,393],{},"Labelling that implied MEDVi was the compounder"," when it was not — FDA treated certain representations as false or misleading \u002F misbranding.",[186,396,397,400],{},[13,398,399],{},"Comparison claims"," (“same active ingredient as…” brand drugs) that can imply FDA approval or evaluation that compounded products do not have.",[10,402,403,404,406],{},"Context that matters for fair ",[13,405,15],{},":",[334,408,409,416,423],{},[186,410,411,412,415],{},"The letter focused on ",[13,413,414],{},"marketing\u002Fmisbranding",", not a public declaration that every vial was contaminated.",[186,417,418,419,422],{},"FDA sent similar letters to ",[13,420,421],{},"many"," compounded GLP-1 telehealth marketers in the same enforcement wave.",[186,424,425],{},"Still: if your reason to buy was “it’s basically Wegovy cheaper,” that is the belief regulators say is misled by that style of claim.",[10,427,428,431,432,435],{},[13,429,430],{},"Buyer takeaway:"," demand the ",[13,433,434],{},"pharmacy name",", compounding oversight story, and clear “not FDA-approved” language — then decide.",[60,437,439],{"id":438},"bbb-trustpilot-and-the-split-record","BBB, Trustpilot, and the Split Record",[10,441,442,443,406],{},"This is the core paradox in ",[13,444,15],{},[334,446,447,453],{},[186,448,449,452],{},[13,450,451],{},"Trustpilot \u002F app-style sentiment:"," large sample, often mid-4★ — patients praise speed, support replies, and weight progress.",[186,454,455,458,459,461,462,465],{},[13,456,457],{},"BBB:"," frequently ",[13,460,134],{},", with complaint clusters on ",[13,463,464],{},"billing, unexpected charges, cancellation timing, refunds",".",[10,467,468,469,472,473,476],{},"Both can be true. A company can ship medication that “works” for many people ",[56,470,471],{},"and"," frustrate a loud minority (and regulators) on money and claims. NexReview weights ",[13,474,475],{},"transparency and billing clarity"," hard — hence a mid-6s overall rather than an 8+.",[60,478,480],{"id":479},"how-the-program-feels-day-to-day","How the Program Feels Day to Day",[10,482,483,486],{},[13,484,485],{},"Intake:"," 5–15 minutes of medical Q&A. Upload what they ask for. Incomplete honesty risks unsafe prescribing.",[10,488,489,492],{},[13,490,491],{},"Approval:"," Not automatic. Contraindications (e.g. personal\u002Ffamily medullary thyroid carcinoma history, MEN2, pregnancy, serious hypersensitivity, and other red flags your clinician will screen) can mean a no.",[10,494,495,498],{},[13,496,497],{},"Shipment:"," Cold-chain packaging for injectables is expected; track packages. Delays appear in some negative reviews — plan refills early.",[10,500,501,504],{},[13,502,503],{},"Side effects:"," Nausea, vomiting, constipation\u002Fdiarrhea, abdominal discomfort are common, especially after titration. Serious risks (pancreatitis, gallbladder issues, dehydration-related kidney injury, etc.) require urgent medical attention — telehealth messaging is not an ER.",[10,506,507,510],{},[13,508,509],{},"Lifestyle:"," Protein intake, resistance training, and nutrition still matter. Medication is not a substitute for medical follow-up if you have diabetes, gallstones history, or complex polypharmacy.",[60,512,514],{"id":513},"who-medvi-is-for-and-who-should-skip","Who MEDVi Is For (and Who Should Skip)",[209,516,518],{"id":517},"reasonable-fit","Reasonable fit",[334,520,521,524,527,534],{},[186,522,523],{},"US adults who already qualify clinically for GLP-1 weight therapy",[186,525,526],{},"People who want cash-pay telehealth convenience over clinic waitlists",[186,528,529,530,533],{},"Patients specifically comparing ",[13,531,532],{},"oral vs injectable"," compounded options",[186,535,536],{},"Buyers who will screenshot prices, set cancel reminders, and accept compounded uncertainty",[209,538,540],{"id":539},"poor-fit","Poor fit",[334,542,543,550,557,560],{},[186,544,545,546,549],{},"Anyone who needs an ",[13,547,548],{},"FDA-approved"," brand product and insurance billing as primary path",[186,551,552,553,556],{},"People who cannot afford ",[13,554,555],{},"maintenance"," pricing for 3–6+ months",[186,558,559],{},"Patients with complex contraindications who need in-person specialist care",[186,561,562],{},"Shoppers who refuse to verify pharmacy \u002F FDA status and want a “miracle shot” ad",[209,564,566],{"id":565},"alternatives-mindset","Alternatives mindset",[10,568,569],{},"Compare flat-price competitors, in-person obesity medicine clinics, and brand prescriptions through your own doctor\u002Finsurance. Convenience is a feature; it is not the only feature.",[60,571,573],{"id":572},"medvi-reviews-vs-typical-competitor-checklist","Medvi Reviews vs Typical Competitor Checklist",[10,575,576,577,579],{},"When you open five tabs of ",[13,578,15],{}," and competitor pages, use the same checklist so marketing fluff cannot hide:",[65,581,582,595],{},[68,583,584],{},[71,585,586,589,592],{},[74,587,588],{},"Checkpoint",[74,590,591],{},"Why it matters",[74,593,594],{},"What “good” looks like",[81,596,597,608,619,630,641,652,663],{},[71,598,599,602,605],{},[86,600,601],{},"Maintenance price in writing",[86,603,604],{},"Intro pricing is a sales tool",[86,606,607],{},"Flat or capped across doses",[71,609,610,613,616],{},[86,611,612],{},"Named compounding pharmacy",[86,614,615],{},"Traceability after FDA labelling concerns",[86,617,618],{},"Public 503A\u002F503B identity + testing story",[71,620,621,624,627],{},[86,622,623],{},"“Not FDA-approved” language",[86,625,626],{},"Avoids Wegovy\u002FZepbound confusion",[86,628,629],{},"Explicit, near the product claim",[71,631,632,635,638],{},[86,633,634],{},"Cancel window",[86,636,637],{},"Top BBB pain point",[86,639,640],{},"Clear cutoff before next charge\u002Fship",[71,642,643,646,649],{},[86,644,645],{},"Labs & contraindications",[86,647,648],{},"Safety > speed",[86,650,651],{},"Honest screen; labs when clinically needed",[71,653,654,657,660],{},[86,655,656],{},"Support channel",[86,658,659],{},"Dose nausea at 11pm happens",[86,661,662],{},"Documented messaging \u002F after-hours path",[71,664,665,668,671],{},[86,666,667],{},"Guarantee fine print",[86,669,670],{},"“Risk-free” ads oversell",[86,672,673],{},"Multi-month rules, fee deductions listed",[10,675,676],{},"If a sales page fails three or more rows, treat five-star screenshots with skepticism — even if weight-loss anecdotes sound real.",[60,678,680],{"id":679},"practical-onboarding-script-copypaste-mentally","Practical Onboarding Script (Copy\u002FPaste Mentally)",[10,682,683],{},"Before you hit pay on MEDVi or any peer:",[183,685,686,693,700,703,706,713],{},[186,687,688,689,692],{},"Screenshot the ",[13,690,691],{},"full cart total",", renewal amount, and next bill date.",[186,694,695,696,699],{},"Ask chat\u002Fsupport: “What is my ",[13,697,698],{},"exact"," price at the highest titration dose on this plan?”",[186,701,702],{},"Ask: “Which pharmacy compounds this, and where can I read the label?”",[186,704,705],{},"Ask: “If I cancel on day X, do I still get charged for shipment Y?”",[186,707,708,709,712],{},"Calendar a cancel review ",[13,710,711],{},"48 hours before"," renewal.",[186,714,715],{},"Save provider messages about side effects — useful if care is later disputed.",[10,717,718,719,465],{},"This is boring. Boring is how you avoid becoming the next one-star billing thread other people read when they search ",[13,720,721],{},"medvi reviews",[60,723,725],{"id":724},"safety-notes-patients-skip-in-ads","Safety Notes Patients Skip in Ads",[10,727,728],{},"GLP-1 receptor agonists (and dual agonists like tirzepatide) change appetite and gastric emptying. That can help weight — and can complicate other meds, surgery timing, and nutrition. Tell clinicians about:",[334,730,731,734,737,740,743,746,749],{},[186,732,733],{},"Personal or family history of medullary thyroid carcinoma \u002F MEN2",[186,735,736],{},"Pancreatitis history",[186,738,739],{},"Gallbladder disease",[186,741,742],{},"Severe GI disease \u002F gastroparesis",[186,744,745],{},"Pregnancy plans or breastfeeding",[186,747,748],{},"Diabetic retinopathy monitoring needs",[186,750,751],{},"All current prescriptions (including psychiatric and diabetes drugs)",[10,753,754,755,758],{},"Telehealth is legitimate care delivery. It is still ",[13,756,757],{},"medical care",". If you feel dismissed after a two-minute checkbox intake, pause.",[10,760,761],{},[49,762],{"alt":763,"src":764},"Medvi Reviews (2026) — decision checklist","\u002Fimages\u002Fmedvi-reviews-combat.webp",[10,766,767],{},[56,768,769],{},"Decide with checklist, not ads — Wikimedia Commons",[60,771,773],{"id":772},"pros-and-cons","Pros and Cons",[65,775,776,786],{},[68,777,778],{},[71,779,780,783],{},[74,781,782],{},"Pros",[74,784,785],{},"Cons",[81,787,788,796,804,812,820],{},[71,789,790,793],{},[86,791,792],{},"Convenient telehealth funnel",[86,794,795],{},"Compounded ≠ FDA-approved brands",[71,797,798,801],{},[86,799,800],{},"Semaglutide + tirzepatide options",[86,802,803],{},"FDA marketing\u002Flabelling warning (2026)",[71,805,806,809],{},[86,807,808],{},"Oral and injectable formats often available",[86,810,811],{},"BBB F \u002F billing & cancel complaints",[71,813,814,817],{},[86,815,816],{},"Strong volume of positive patient reviews",[86,818,819],{},"Month-two \u002F dose-based price surprise risk",[71,821,822,825],{},[86,823,824],{},"Provider messaging commonly included",[86,826,827],{},"Pharmacy transparency historically weak",[60,829,831],{"id":830},"nexreview-verdict","NexReview Verdict",[10,833,834,836,837,839,840,843],{},[13,835,15],{}," should not be a yes\u002Fno slogan. MEDVi is a large, convenient GLP-1 telehealth operator that many patients rate highly for access and support — ",[13,838,471],{}," a cash-pay compounded-drug seller with documented billing friction plus a ",[13,841,842],{},"2026 FDA warning letter"," on misleading product presentation.",[10,845,846,849,850,465,853,856,859],{},[13,847,848],{},"Consider"," only if a clinician confirms you are a candidate, you understand compounded limits, and you have written clarity on ",[13,851,852],{},"maintenance price + cancel rules",[854,855],"br",{},[13,857,858],{},"Skip"," if you need brand FDA-approved therapy, insurance-first pricing, or zero tolerance for subscription billing ambiguity.",[10,861,862,865],{},[13,863,864],{},"Final score: 6.8\u002F10"," — conditional, transparency-first recommendation.",[60,867,869],{"id":868},"faq-medvi-reviews","FAQ — Medvi Reviews",[209,871,873],{"id":872},"is-medvi-legit-or-a-scam","Is MEDVi legit or a scam?",[10,875,876],{},"It is a real telehealth business shipping prescribed compounded GLP-1 programs at scale — not a random “pay and disappear” scam. Legitimacy ≠ “risk-free” or “FDA-approved compounded drug.”",[209,878,880],{"id":879},"is-medvi-the-same-as-medvidi","Is MEDVi the same as MEDvidi?",[10,882,883],{},"No. Different companies. Check domain names before trusting a star rating.",[209,885,887],{"id":886},"are-medvis-compounded-glp-1s-fda-approved","Are MEDVi’s compounded GLP-1s FDA-approved?",[10,889,890],{},"No. FDA-approved examples include specific brand products (e.g. Wegovy, Zepbound) under their labels. Compounded versions are different regulatory category.",[209,892,894],{"id":893},"what-did-the-fda-warning-letter-say","What did the FDA warning letter say?",[10,896,897],{},"In short: misleading labelling\u002Fmarketing around compounding identity and claims that can imply FDA approval\u002Fevaluation. Read the FDA letter text for primary source detail.",[209,899,901],{"id":900},"why-do-medvi-reviews-look-great-and-bbb-look-terrible","Why do Medvi reviews look great and BBB look terrible?",[10,903,904],{},"Different populations and issues. Clinical convenience earns stars; billing\u002Fcancel disputes drive BBB complaints. Read both.",[209,906,908],{"id":907},"how-much-does-medvi-cost","How much does MEDVi cost?",[10,910,911],{},"Verify live checkout. 2026 third-party coverage often cites ~$179 entry for compounded semaglutide and ~$279–$299 ranges for tirzepatide — with complaints about later increases. Ask for month-2 and maintenance quotes.",[209,913,915],{"id":914},"can-i-cancel-anytime","Can I cancel anytime?",[10,917,918,919,922],{},"Marketed as month-to-month, but ",[13,920,921],{},"timing"," relative to shipment\u002Fbilling is a top complaint. Cancel in writing\u002Fscreenshots before the next charge window.",[209,924,926],{"id":925},"will-i-lose-weight-on-medvi","Will I lose weight on MEDVi?",[10,928,929],{},"Individual results vary. Brand clinical trials do not automatically equal compounded outcomes. Pair any medication with medical follow-up and sustainable habits.",[209,931,933],{"id":932},"does-nexreview-take-commissions","Does NexReview take commissions?",[10,935,936,937,939],{},"This article is an editorial review for readers searching ",[13,938,721],{},". Always re-check live terms, state eligibility, and your clinician’s guidance — policies change.",{"title":941,"searchDepth":942,"depth":942,"links":943},"",2,[944,945,946,953,954,955,956,957,962,963,964,965,966,967],{"id":62,"depth":942,"text":63},{"id":177,"depth":942,"text":178},{"id":206,"depth":942,"text":207,"children":947},[948,950,951,952],{"id":211,"depth":949,"text":212},3,{"id":225,"depth":949,"text":226},{"id":232,"depth":949,"text":233},{"id":246,"depth":949,"text":247},{"id":272,"depth":942,"text":273},{"id":370,"depth":942,"text":371},{"id":438,"depth":942,"text":439},{"id":479,"depth":942,"text":480},{"id":513,"depth":942,"text":514,"children":958},[959,960,961],{"id":517,"depth":949,"text":518},{"id":539,"depth":949,"text":540},{"id":565,"depth":949,"text":566},{"id":572,"depth":942,"text":573},{"id":679,"depth":942,"text":680},{"id":724,"depth":942,"text":725},{"id":772,"depth":942,"text":773},{"id":830,"depth":942,"text":831},{"id":868,"depth":942,"text":869,"children":968},[969,970,971,972,973,974,975,976,977],{"id":872,"depth":949,"text":873},{"id":879,"depth":949,"text":880},{"id":886,"depth":949,"text":887},{"id":893,"depth":949,"text":894},{"id":900,"depth":949,"text":901},{"id":907,"depth":949,"text":908},{"id":914,"depth":949,"text":915},{"id":925,"depth":949,"text":926},{"id":932,"depth":949,"text":933},"Software Reviews","Medvi reviews for 2026 — MEDVi GLP-1 weight loss telehealth (semaglutide\u002Ftirzepatide), pricing, compounded vs brand, FDA warning letter, BBB, cancel\u002Fbilling issues, and who should join.","md",{},true,"\u002Fmedvi-reviews","2026-08-27",{"overall":986,"verdict":987,"scores":988,"pros":1004,"cons":1009},6.8,"Convenient GLP-1 Access — Verify Pricing, Pharmacy & Claims",[989,992,995,998,1001],{"label":990,"value":991},"Convenience",8.4,{"label":993,"value":994},"Clinical Access",7.6,{"label":996,"value":997},"Pricing Clarity",5.4,{"label":999,"value":1000},"Transparency",5.2,{"label":1002,"value":1003},"Support Responsiveness",7,[1005,1006,1007,1008],"Fast telehealth path to medically supervised GLP-1 care in many US states","Compounded semaglutide and tirzepatide in injectable and oral formats","Month-to-month model with provider messaging commonly included","Large volume of positive patient reviews for convenience and results",[1010,1011,1012,1013],"Compounded GLP-1s are not FDA-approved like Wegovy\u002FZepbound","FDA warning letter (Feb 2026) cited misleading marketing\u002Flabelling","BBB F rating with recurring billing, price-jump, and cancel complaints","Pharmacy identity and maintenance-dose price often unclear at signup",{"title":5,"description":979},{"loc":983,"lastmod":984,"changefreq":1016,"priority":1017},"monthly",0.92,"medvi-reviews","uOGy0FvZHJ1k6dLzXKAfAxUrlPCFW0_75YQfPNdbv28",1789303234649]